Cargando…

A New Rodent Model of Non-Alcoholic Steatohepatitis and Metabolic Syndrome

Detalles Bibliográficos
Autores principales:	Romeiro, Fernando Gomes, Santos, Lívia Alves Amaral
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Cardiologia - SBC 2019
Materias:	Short Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020952/ https://www.ncbi.nlm.nih.gov/pubmed/31800715 http://dx.doi.org/10.5935/abc.20190219

Ejemplares similares

Metabolic comorbidity, the new enemy. Metabolic syndrome and steatohepatitis
por: Rivera Esteban, JM, et al.
Publicado: (2020)

Diagnosis and Management of Cirrhosis-Related Osteoporosis
por: Santos, Lívia Alves Amaral, et al.
Publicado: (2016)

Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management
por: Salomone, Federico, et al.
Publicado: (2015)

Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome
por: Ramalho, F. N., et al.
Publicado: (2017)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
por: Stefano, J.T., et al.
Publicado: (2015)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
por: Shiina, Shuichiro, et al.
Publicado: (2023)

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
por: Hattori, Sachiko, et al.
Publicado: (2021)

Innate Lymphoid Cells: New Culprits of Alcohol-Associated Steatohepatitis
por: Choi, Sung Eun, et al.
Publicado: (2022)

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
por: Qiang, Shirong, et al.
Publicado: (2015)

Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?
por: Jeong, Soung Won
Publicado: (2020)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

The Apelin Receptor APJ in Hematopoietic Stem Cells/Progenitor Cells in the Early Stage of Non-Alcoholic Steatohepatitis
por: Ando, Wataru, et al.
Publicado: (2017)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)
por: Sekhon, Anupamjeet Kaur, et al.
Publicado: (2021)

Which Metabolic Index is Appropriate for Predicting Non-alcoholic Steatohepatitis?
por: Jamali, Raika, et al.
Publicado: (2020)

The regulatory state of nonalcoholic steatohepatitis and metabolism
por: Omokaro, Stephanie O., et al.
Publicado: (2020)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
por: Eeckhoute, Jérôme
Publicado: (2022)

Effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix components in experimentally induced non-alcoholic steatohepatitis
por: Mohan, Surapaneni Krishna, et al.
Publicado: (2015)

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
por: Tovo, Cristiane Valle, et al.
Publicado: (2023)

Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
por: dos Santos, João Paulo Margiotti, et al.
Publicado: (2022)

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
por: Yoshiji, Hitoshi, et al.
Publicado: (2009)

Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) – A single arm clinical trial.
por: Tarapure, Shruti, et al.
Publicado: (2021)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

mTOR Activation in Liver Tumors Is Associated with Metabolic Syndrome and Non-Alcoholic Steatohepatitis in Both Mouse Models and Humans
por: Okuno, Takahiro, et al.
Publicado: (2018)

Fibroscan-AST (FAST) score and other non-invasive tests for the diagnosis of fibrotic non-alcoholic steatohepatitis
por: Chan, Wah Loong, et al.
Publicado: (2023)

An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
por: Marin, Veronica, et al.
Publicado: (2016)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: A population-based study()
por: Ghoneim, Sara, et al.
Publicado: (2020)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice
por: Willebrords, Joost, et al.
Publicado: (2017)

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2014)

The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights
por: Federico, Alessandro, et al.
Publicado: (2021)

Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
por: Brar, Gurmehr, et al.
Publicado: (2019)

Endothelial dysfunction in patients with non-alcoholic steatohepatitis
por: Onal, Ibrahim Koral
Publicado: (2014)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

Conophylline inhibits non-alcoholic steatohepatitis in mice
por: Nakade, Yukiomi, et al.
Publicado: (2017)

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
por: Zhu, Bo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_91ium5ta2i2j78alb7veuo9sac